IMPROVING HEALTH THROUGH TRANSFORMATIVE THERAPIES AND DISRUPTIVE TECHNOLOGIES
Hatteras’ mission is to build transformational human medicine companies that benefit patients and the professionals who serve them.
TUNE THERAPEUTICS
A preclinical-stage start-up focused on developing a versatile epigenetic editing platform that uses multiple effectors for a variety of applications.
VIEW PORTFOLIO
ATACOR MEDICAL
Developing an extracardiac, extravascular approach to cardiac pacing and defibrillation.
VIEW PORTFOLIO
IRIS HEALTHCARE
Iris delivers improved health outcomes, member experience and cost savings to your plan with our intuitive and customizable Advance Care Planning solutions.
VIEW PORTFOLIO
ATSENA
A clinical-stage AAV gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness.
VIEW PORTFOLIO
STRIDEBIO
Developing engineered viral vectors for gene therapy using structure-inspired design of adeno-aden-associated virus (AAV) vectors that can evade neutralizing antibodies, a current limitation of existing gene therapies.
VIEW PORTFOLIO
G1 THERAPEUTICS
A clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology.
VIEW PORTFOLIO
ELLIGO HEALTH RESEARCH
Providing on-demand clinical research infrastructure to enable large physician practices to offer clinical trial participation to their clients.
VIEW PORTFOLIO
RIBOMETRIX
Developing small molecules that target functional 3D RNA structures to treat human disease.
VIEW PORTFOLIO
CONTEGO MEDICAL
Developing an integrated embolic protection platform to improve the safety and efficacy of catheter-based interventions.
VIEW PORTFOLIO
